My primary focus of interest is the preclinical evaluation of PET imaging ligands. Establishing a pharmacokinetic pig model for the characterization of novel radiotracers to measure pathological alpha-synuclein will be my intent. My curiosity also lies in psychedelic research and the molecular pathways associated with its pharmacological effects.
My primary focus of interest is the preclinical evaluation of PET imaging ligands. Establishing a pharmacokinetic pig model for the characterization of novel radiotracers to measure pathological alpha-synuclein will be my intent. My curiosity also lies in psychedelic research and the molecular pathways associated with its pharmacological effects.